
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5188457/publications.pdf Version: 2024-02-01



ALEY HOLEP

#	Article	IF	CITATIONS
1	Sex differences in brain activation pattern during a visuospatial cognitive task: a functional magnetic resonance imaging study in healthy volunteers. Neuroscience Letters, 2003, 344, 169-172.	2.1	236
2	Association of Olanzapine-Induced Weight Gain With an Increase in Body Fat. American Journal of Psychiatry, 2001, 158, 1719-1722.	7.2	151
3	Gender differences in regional cerebral activity during the perception of emotion: A functional MRI study. NeuroImage, 2006, 32, 854-862.	4.2	143
4	Quality of Life in Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 932-939.	2.2	132
5	Patient outcomes in schizophrenia II: the impact of cognition. European Psychiatry, 2005, 20, 395-402.	0.2	119
6	Osteoporosis in Patients With Schizophrenia. American Journal of Psychiatry, 2005, 162, 162-167.	7.2	114
7	Brain activation pattern during a verbal fluency test in healthy male and female volunteers: a functional magnetic resonance imaging study. Neuroscience Letters, 2003, 352, 191-194.	2.1	104
8	Compliance in Schizophrenia: Psychopathology, Side Effects, and Patients' Attitudes Toward the Illness and Medication. Journal of Clinical Psychiatry, 2004, 65, 1211-1218.	2.2	104
9	Selection Bias in Clinical Trials With Antipsychotics. Journal of Clinical Psychopharmacology, 2000, 20, 699-702.	1.4	94
10	Brain activation patterns during a verbal fluency test?a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophrenia Research, 2004, 70, 287-291.	2.0	91
11	Sex differences in brain activation patterns during processing of positively and negatively valenced emotional words. Psychological Medicine, 2007, 37, 109-119.	4.5	84
12	Language lateralization in unmedicated patients during an acute episode of schizophrenia: A functional MRI study. Psychiatry Research - Neuroimaging, 2006, 146, 185-190.	1.8	82
13	Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. European Psychiatry, 2009, 24, 27-32.	0.2	81
14	Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 246-255.	3.2	77
15	Attitudes Toward Antipsychotics Among Outpatient Clinic Attendees With Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 49-53.	2.2	77
16	Olanzapine Induces Insulin Resistance. Journal of Clinical Psychiatry, 2003, 64, 1436-1439.	2.2	72
17	Facial emotion recognition and its relationship to subjective and functional outcomes in remitted patients with bipolar I disorder. Bipolar Disorders, 2011, 13, 537-544.	1.9	70
18	Brain activation patterns during a selective attention test — a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Research - Neuroimaging, 2007, 154, 31-40.	1.8	69

#	Article	IF	CITATIONS
19	An fMRI Study of Episodic Encoding and Recognition of Words in Patients With Schizophrenia in Remission. American Journal of Psychiatry, 2003, 160, 911-918.	7.2	65
20	Social cognition in serious mental illness. Current Opinion in Psychiatry, 2014, 27, 197-202.	6.3	65
21	Brain activation patterns during a selective attention test—a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Research - Neuroimaging, 2003, 123, 1-15.	1.8	64
22	Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. Schizophrenia Research, 2016, 171, 86-91.	2.0	63
23	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.7	60
24	Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry, 2005, 20, 386-394.	0.2	59
25	Theory of mind and its relevance in schizophrenia. Current Opinion in Psychiatry, 2012, 25, 71-75.	6.3	56
26	Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and selfâ€esteem. Acta Psychiatrica Scandinavica, 2016, 134, 360-367.	4.5	56
27	Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. Schizophrenia Research, 2016, 175, 148-153.	2.0	50
28	Attitudes of Patients With Schizophrenia Toward Placebo-Controlled Clinical Trials. Journal of Clinical Psychiatry, 2003, 64, 277-281.	2.2	50
29	Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. European Psychiatry, 2017, 46, 42-47.	0.2	47
30	Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Journal of Clinical Psychiatry, 2004, 65, 932-9.	2.2	44
31	Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychological Medicine, 2011, 41, 2131-2139.	4.5	42
32	Facial affect recognition in symptomatically remitted patients with schizophrenia and bipolar disorder. Schizophrenia Research, 2014, 152, 440-445.	2.0	42
33	Neural Correlates of Episodic Encoding and Recognition of Words in Unmedicated Patients During an Acute Episode of Schizophrenia: A Functional MRI Study. American Journal of Psychiatry, 2003, 160, 1802-1808.	7.2	39
34	Prolactin Levels and Sexual Adverse Effects in Patients With Schizophrenia During Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 711-715.	1.4	38
35	Neutropenia Induced by Second Generation Antipsychotics: A Prospective Investigation. Pharmacopsychiatry, 2010, 43, 41-44.	3.3	37
36	Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatrica Scandinavica, 2007, 116, 354-361.	4.5	36

#	Article	IF	CITATIONS
37	Early changes of plasma lipids during treatment with atypical antipsychotics. International Clinical Psychopharmacology, 2006, 21, 369-372.	1.7	31
38	Neural substrates for episodic encoding and recognition of unfamiliar faces. Brain and Cognition, 2007, 63, 174-181.	1.8	31
39	Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. Journal of Affective Disorders, 2018, 238, 399-404.	4.1	31
40	Sex matters: stress perception and the relevance of resilience and perceived social support in emerging adults. Archives of Women's Mental Health, 2021, 24, 403-411.	2.6	30
41	Quetiapine Cross Reactivity With Urine Methadone Immunoassays. American Journal of Psychiatry, 2007, 164, 172-172.	7.2	29
42	Cognitive impairment in schizophrenia: Clinical ratings are not a suitable alternative to neuropsychological testing. Schizophrenia Research, 2007, 92, 126-131.	2.0	27
43	Emotional Intelligence and cognitive abilities – associations and sex differences. Psychology, Health and Medicine, 2017, 22, 1001-1010.	2.4	27
44	Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international crossâ€sectional study. Acta Psychiatrica Scandinavica, 2018, 137, 316-327.	4.5	27
45	Self-stigma versus stigma resistance in schizophrenia: Associations with resilience, premorbid adjustment, and clinical symptoms. Psychiatry Research, 2019, 271, 396-401.	3.3	27
46	Social interaction reward: A resilience approach to overcome vulnerability to drugs of abuse. European Neuropsychopharmacology, 2020, 37, 12-28.	0.7	25
47	Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophrenia Research, 2009, 113, 246-251.	2.0	24
48	Attitudes towards medication in patients with schizophrenia. Acta Psychiatrica Scandinavica, 2006, 113, 161-162.	4.5	21
49	Emotional Intelligence deficits in schizophrenia: The impact of non-social cognition. Schizophrenia Research, 2016, 172, 131-136.	2.0	21
50	Antipsychotic-induced tardive dyskinesia. Current Opinion in Psychiatry, 2019, 32, 179-184.	6.3	21
51	Social interaction reward in rats has antiâ€stress effects. Addiction Biology, 2021, 26, e12878.	2.6	21
52	The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophrenia Research, 2005, 75, 143-146.	2.0	20
53	Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder. Psychological Medicine, 2017, 47, 35-42.	4.5	20
54	Outcomes in Schizophrenia Outpatients Treated with Amisulpride or Olanzapine. Pharmacopsychiatry, 2007, 40, 1-8.	3.3	19

#	Article	IF	CITATIONS
55	Affective prosody perception in symptomatically remitted patients with schizophrenia and bipolar disorder. Schizophrenia Research, 2014, 158, 100-104.	2.0	19
56	ls p38 MAPK Associated to Drugs of Abuse-Induced Abnormal Behaviors?. International Journal of Molecular Sciences, 2020, 21, 4833.	4.1	19
57	Psychological Distress, Loneliness, and Boredom Among the General Population of Tyrol, Austria During the COVID-19 Pandemic. Frontiers in Psychiatry, 2021, 12, 691896.	2.6	19
58	The Mediating Role of Resilience and Extraversion on Psychological Distress and Loneliness Among the General Population of Tyrol, Austria Between the First and the Second Wave of the COVID-19 Pandemic. Frontiers in Psychiatry, 2021, 12, 766261.	2.6	18
59	QTc Variability in Schizophrenia Patients Treated With Antipsychotics and Healthy Controls. Journal of Clinical Psychopharmacology, 2005, 25, 206-210.	1.4	17
60	The neural regions sustaining episodic encoding and recognition of objects. Brain and Cognition, 2007, 63, 159-166.	1.8	17
61	The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology, 2003, 6, 201-206.	2.1	16
62	Association Between Antipsychotic-induced Elevation of Liver Enzymes and Weight Gain. Journal of Clinical Psychopharmacology, 2006, 26, 500-503.	1.4	16
63	Neurology Issues in Schizophrenia. Current Psychiatry Reports, 2015, 17, 32.	4.5	16
64	Associations between resilience and quality of life in patients experiencing a depressive episode. Psychiatry Research, 2020, 292, 113353.	3.3	16
65	Sibutramine in the treatment of antipsychotic-induced weight gain. International Clinical Psychopharmacology, 2014, 29, 181-184.	1.7	15
66	Aripiprazole Use in Early Pregnancy: A Case Report. Pharmacopsychiatry, 2012, 45, 299-300.	3.3	14
67	Pulmonary Embolism and Aspiration Pneumonia After Reexposure to Clozapine. Journal of Clinical Psychopharmacology, 2014, 34, 385-387.	1.4	14
68	Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. Journal of Psychopharmacology, 2007, 21, 400-404.	4.0	13
69	Risk of violence of inpatients with severe mental illness – Do patients with schizophrenia pose harm to others?. Psychiatry Research, 2014, 219, 450-456.	3.3	13
70	Emotional Intelligence and resilience in mental health professionals caring for patients with serious mental illness. Psychology, Health and Medicine, 2016, 21, 755-761.	2.4	13
71	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry, 2022, 13, 826465.	2.6	13
72	Combined Clozapine and Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia. Journal of ECT, 2011, 27, e61-e62.	0.6	12

#	Article	IF	CITATIONS
73	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. International Clinical Psychopharmacology, 2013, 28, 1.	1.7	12
74	Erratum. Journal of Clinical Psychopharmacology, 2005, 25, 201.	1.4	11
75	Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry, 2018, 18, 212.	2.6	11
76	Attitudes of patients with schizophrenia and depression towards psychiatric research. Psychiatry Research, 2010, 177, 172-176.	3.3	10
77	Bilirubin Concentration Correlates With Positive Symptoms in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 512-516.	2.2	10
78	Mental health in individuals with severe mental disorders during the covid-19 pandemic: a longitudinal investigation. NPJ Schizophrenia, 2022, 8, 17.	3.6	10
79	Measuring Adherence to Medication in Schizophrenia: The Relationship between Attitudes toward Drug Therapy and Plasma Levels of New-Generation Antipsychotics. International Journal of Neuropsychopharmacology, 2015, 18, pyu091-pyu091.	2.1	9
80	Why do indiviuals with schizophrenia drop out of observational clinical trials?. Psychiatry Research, 2017, 256, 1-5.	3.3	9
81	Emotional intelligence in bipolar-I-disorder: A comparison between patients, unaffected siblings, and control subjects. European Psychiatry, 2020, 63, e69.	0.2	9
82	On the difficulties of building therapeutic relationships when wearing face masks. Journal of Psychosomatic Research, 2020, 138, 110226.	2.6	9
83	Resilience Predicts Self-Stigma and Stigma Resistance in Stabilized Patients With Bipolar I Disorder. Frontiers in Psychiatry, 2021, 12, 678807.	2.6	9
84	Management of a Risperidone-Induced Tardive Pisa Syndrome. Journal of Clinical Psychopharmacology, 2012, 32, 418-420.	1.4	8
85	Prosodic and Semantic Affect Perception in Remitted Patients With Bipolar I Disorder. Journal of Clinical Psychiatry, 2015, 76, e779-e786.	2.2	8
86	Rewarding Social Interaction in Rats Increases CaMKII in the Nucleus Accumbens. Biomedicines, 2021, 9, 1886.	3.2	8
87	Psychiatric misdiagnoses in Dandy–Walker variant. Neurocase, 2015, 21, 499-500.	0.6	7
88	Involvement of cAMP-Dependent Protein Kinase in the Nucleus Accumbens in Cocaine Versus Social Interaction Reward. International Journal of Molecular Sciences, 2021, 22, 345.	4.1	7
89	Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting. European Neuropsychopharmacology, 2016, 26, 717-728.	0.7	6
90	Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report. Frontiers in Psychiatry, 2020, 11, 413.	2.6	6

#	Article	IF	CITATIONS
91	Advances in the neuroimaging of cognitive functions in schizophrenia. Current Opinion in Psychiatry, 2002, 15, 3-7.	6.3	5
92	Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2015, 35, 474-475.	1.4	5
93	Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics. Journal of Clinical Psychopharmacology, 2016, 36, 621-627.	1.4	4
94	Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With Schizophrenia. Frontiers in Psychiatry, 2020, 11, 570857.	2.6	4
95	Is It Possible to Shift from Down to Top Rank? A Focus on the Mesolimbic Dopaminergic System and Cocaine Abuse. Biomedicines, 2021, 9, 877.	3.2	4
96	Psychopharmakotherapie in der Rehabilitation. , 2004, , 129-133.		4
97	Reply to Psychotic Symptoms Associated With Topiramate: Cognitive Side Effects or Worsening of Psychosis?. Journal of Clinical Psychiatry, 2004, 65, 1145-1146.	2.2	4
98	Neurometabolite correlates with personality and stress in healthy emerging adults: A focus on sex differences. NeuroImage, 2022, 247, 118847.	4.2	3
99	Is Emotional Intelligence Impaired in Unaffected Siblings of Patients with Schizophrenia?. Journal of the International Neuropsychological Society, 2017, 23, 577-583.	1.8	2
100	Ability-based emotional intelligence in schizophrenia. Current Opinion in Psychiatry, 2017, 30, 197-200.	6.3	2
101	Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period. International Clinical Psychopharmacology, 2018, 33, 197-203.	1.7	2
102	Combined Processing of Facial and Vocal Emotion in Remitted Patients With Bipolar I Disorder. Journal of the International Neuropsychological Society, 2019, 25, 275-284.	1.8	2
103	The relationship between emotional intelligence and quality of life in schizophrenia and bipolar I disorder. Quality of Life Research, 2021, 30, 2475-2485.	3.1	2
104	Pharmacological Strategies to Enhance Adherence in Schizophrenia. , 2014, , 85-97.		2
105	The Anti-social Brain in Schizophrenia: A Role of CaMKII?. Frontiers in Psychiatry, 2022, 13, .	2.6	2
106	Pharmacological Interventions. Key Issues in Mental Health, 2010, , 145-157.	0.6	1
107	Aripiprazole Add-On Treatment in a Patient with Schizoaffective Disorder: Neurocognitive Outcomes. Pharmacopsychiatry, 2010, 43, 234-235.	3.3	1
108	Therapeutic Alliance in Patients With Schizophrenia: Introduction of a New Rating Instrument. Journal of Psychiatric Practice, 2016, 22, 298-307.	0.7	1

#	Article	IF	CITATIONS
109	Schizophrene Störungen. , 2008, , 847-872.		1
110	Schizophrenie, schizotype und wahnhafte Störungen (ICD-10 F2). , 2012, , 111-151.		1
111	Characteristics of Involuntarily Admitted Patients and Treatment Patterns Over a 21-Year Observation Period. Journal of Clinical Psychopharmacology, 2018, 38, 376-379.	1.4	0
112	Evolución de los pacientes en la esquizofrenia I: correlatos con variables sociodemográficas, manifestaciones psicopatológicas y efectos secundarios. European Psychiatry (Ed EspaA±ola), 2006, 13, 77-85.	0.0	0
113	Evolución de los pacientes en la esquizofrenia II: el impacto de la cognicién. European Psychiatry (Ed) Tj ETQq	1 1.0.784	314 rgBT /0\